Hematology

The FDA has approved luspatercept to treat anemia in patients with lower-risk myelodysplastic syndromes.

Among patients with symptomatic Waldenström macroglobulinemia, the very good partial response rate with zanubrutinib was 36.3% vs 25.3% with ibrutinib.

The FDA has granted ivosidenib priority review designation based on data from a phase 1 trial.

The FDA has granted accelerated approval to elranatamab-bcmm to treat adults with relapsed or refractory multiple myeloma who have already undergone 4 prior lines of treatment.

Patients with relapsed/refractory primary mediastinal large B-cell lymphoma achieved antitumor responses with pembrolizumab.

Amanda Warner, MS, BSN, RN, OCN, who is manager of research informatics & real world evidence with Florida Cancer Specialists & Research Institute, provides an in-depth look at teclistamab in a downloadable fact sheet.

Talquetamab has received accelerated approval for patients with relapsed or refractory multiple myeloma.

The resubmitted biologics license application for remestemcel-L has been issued a complete response letter.

The FDA has issued a complete response letter to the biologics license application for denileukin diftitox.

The first-line combination of magrolimab and azacitidine will no longer be investigated in patients with higher-risk myelodysplastic syndrome.

The FDA has approved LeukoStrat CDx FLT3, a companion diagnostic, to help identify patients with FLT3-ITD–positive acute myeloid leukemia who are eligible to receive quizartinib.

CB-010 led to a 94% overall response rate among 16 patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Quizartinib has been approved by the FDA for use with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy after consolidation chemotherapy, to treat adults with newly diagnosed acute myeloid leukemia that is FLT3-ITD positive, as detected by an FDA-approved test.

Third-line lisocabtagene maraleucel induced a response in 97% of patients with relapsed or refractory follicular lymphoma.

Intensified doxorubicin, bleomycin, vinblastine, dacarbazine, and granulocyte colony–stimulating factor (ABVD) was associated with a 56% reduction in the relative risk of 3-year progression, relapse, or death.

Glofitamab monotherapy led to a 63.6% overall response rate in heavily pretreated patients with Richter syndrome.

Pirtobrutinib was associated with a 19.6-month median progression-free survival in patients with heavily pretreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

The complete response or complete response with incomplete bone marrow recovery rate was 61% for patients with chronic lymphocytic leukemia and high-risk disease.

The National Comprehensive Cancer Network has updated their guidelines on high-dose methotrexate and glucarpidase.

Patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor achieved preliminary responses with the CD20-targeted CAR T-cell therapy MB-106.

Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, highlight the importance of improving inpatient ambulation for transplant patients.

For patients with myelofibrosis receiving pacritinib, spleen volume reduction was associated with improved overall survival.

Natasha Kormanik MSN, CRNP, FNP-BC, OCN, discusses accelerated vs regular approvals in hematologic oncology and how it applies to approved PI3K inhibitors.

Phase 3 findings from the CLL12 trial support a watch-and-wait approach over systemic treatment with ibrutinib for patients with asymptomatic early-stage chronic lymphocytic leukemia.

The phase 1/2 TRANSCEND CLL 004 trial met its primary end point by demonstrating that lisocabtagene maraleucel elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

The FDA has granted blinatumomab full approval for patients with minimal residual disease–positive B-cell acute lymphoblastic leukemia.

Glofitamab has received accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma.

Patients with relapsed/refractory multiple myeloma treated with elranatamab following any prior BCMA-directed therapy achieved an overall response rate of 46%.

Omitting radiotherapy did not compromise overall survival rates for patients with primary mediastinal B-cell lymphoma.

Sabrina Banegas, RN, BMT-CN, highlights the value of improving antibiotic administration times for patients undergoing bone marrow transplant.